

3-4-02

DNAX RESEARCH INSTITUTE

901 California Avenue
Palo Alto, CA 94304-1104
(650) 852-9196

Customer number 028008

Box: Patent Application
US Patent and Trademark Office,
Arlington, VA 22202

Honorable Sir:

Transmitted herewith for filing under 37 CFR 1.53(b) is the:

- [] patent application, [] continuation patent
application, [] divisional patent application
[X] continuation-in-part (CIP) patent application of:



Express Mail Label No. EL 789 848 721 US

Date of Deposit is February 28, 2002

I hereby certify that this is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box: Patent Application, Washington, D. C. 20231.

By:

Lois E. Miller,

date

PATENT/DX0644KBK

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rene DE WAAL MALEFYT, et al.

Serial No.: not yet assigned

Filed: February 28, 2002

For: MAMMALIAN CYTOKINE;
RELATED REAGENTS

Examiner: not assigned

Art Unit: not assigned

COMPUTER READABLE SEQUENCE
SUBMISSION

Palo Alto, California 94304

February 28, 2002

Assistant Commissioner for Patents
Box: Patent Application
Washington, D.C. 20231

Sir:

**COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

In order to comply with requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures, for the above-identified application, in accordance with 37 CFR § 1.821 - 1.825, Applicants hereby submit: (1) a write-protected diskette containing a computer-readable submission for the "Sequence Listing"; and (2) a "Sequence Listing" paper copy of the contents of the diskette.

REMARKS

Enclosed is a write protected floppy diskette with the sequence listing generated by the Patent Office's PATENTIN program. The Diskette should comply with the requirements of 37 CFR §1.824 and is IBM PC compatible with a

PC-DOS/MS-DOS operating system. If the diskette has been damaged, please call Applicants and a replacement diskette will be provided. A hard paper copy printout of the diskette is attached thereto.


I hereby state the informational contents of the paper and computer readable
5 copies of the Sequence Listing, submitted in accordance with 37 CFR 1.821(c) and (e), respectively, are believed to be the same. This submission introduces no new matter, since enclosed sequences are the same as sequences which were submitted in priority documents.

10 Applicants have invested significant labor and care in preparing the present submission. The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence submissions. Should this not be the case, Applicants respectfully request notification of specific deficiencies and an opportunity for remedy, as described in 37 CFR 1.135(c).

15 Applicants believe that no fees are required; however, if any fees are required by the present Response, the Commissioner is authorized to charge any fees or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

20 Dated: February 28, 2002

By: 
Sheela Mohan-Peterson
Attorney for Applicants
Reg. No. 41,201

25 enclosures and attachments:
one write-protected diskette (CRM)
paper copy of contents of diskette (9 pages)

30
35 **Customer Number 028008**
DNAX Research Institute
901 California Avenue
Palo Alto, California 94304-1104
Tel: (650) 852-9196
Fax: (650) 496-1200

Rene DE WAAL MALEFYT, et al., U.S.S.N.: to be assigned

Filed: February 28, 2002, EL 789 848 721 USpage 2 of 2